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Opening Statement
There were several reasons why I chose to obtain a Doctorate of Nursing Practice (DNP)
degree. The main reasons were to learn and develop great clinical skills, to be able to promote
health, to build long and lasting relationships with my patients and their families and to be able
to work with other people to promote real change in our healthcare system. I have always been
interested in pathophysiology and clinical practice. I have a great interest in not just what
happens to people when they get sick but to truly understand the relationship between humans
and health.
My primary goal for my DNP scholarly practice would be to get the training necessary to
be able to provide the best care possible for my patients. Not only would I get the clinical
exposure to learn how the different diseases affect people and how to diagnose and treat those
diseases, I will also be prepared to critique healthcare research in order to incorporate scientific
evidence into patient care that will maximize the scope of my practice and optimally care for my
patients.
Secondly, I want to build a relationship with my patients and their families. My prior
experience has been in the inpatient setting. A primary care DNP education can change my
clinical practice focus from one of brief interactions where I temporize the illnesses of sick
patients to one of building long lasting relationships with my patients and their families where I
can promote them to live healthy and happy lives.
Finally, I want to develop the skills to work with others in a multidisciplinary team and
implement change to better benefit my patients. The DNP program will give me the skills
necessary to function within a team and be recognized for my doctorate degree providing parity
with the other members of the team.
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Abstract
Purpose – To establish an adult Pneumococcal (PCV13) vaccination protocol within a chain of
retail healthcare clinics.
Background - Invasive Pneumococcal disease results in significant morbidity and mortality in
patients ≥65 and those with immunocompromised status. Despite CDC recommendations,
national PCV13 vaccination rates remain low in these populations. No adult PCV13 vaccination
protocol existed in the project retail healthcare clinics.
Project Plan Process – An evidence-based PCV13 vaccination protocol based on the CDC
guidelines using the Provus Discrepancy Evaluation Model as a framework was implemented.
NPs were educated on indications for PCV13 vaccinations and a questionnaire to identify those
patients who qualified. Qualified patients were either vaccinated or referred elsewhere for
vaccination. The EMR system was reviewed to determine the number of patients who qualified
for the PCV13 vaccination who were screened.
Results: Of the 3,202 patients, 4-6% qualified for the PCV13 vaccination, 27.7% were identified
and offered the PCV13 vaccination and 11% were vaccinated or referred elsewhere for
vaccination. Regarding age, 65.2% of patients who qualified for PCV13 were ≥65 in contrast to
34.8% who were 19-64 years old. As for those patients who were actually vaccinated, 76.5%
were ≥65 while 23.5% were 19-64 years old.
Conclusions/Implications - Retail health care clinics can be an effective venue for providing
essential vaccinations. Nurse practitioners are well prepared with the knowledge base and skill
set to assume a leadership role in the development of vaccination programs within our
communities.
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Introduction
Public health initiative programs have been extremely successful resulting in the
eradication of several very dangerous communicable diseases such as smallpox, diphtheria and
polio by the use of vaccinations (Center for Disease Control and Prevention, 1999). Childhood
vaccinations have succeeded in decreasing childhood mortality for those over a year old by 99%
(Center for Disease Control and Prevention, 1999). However, the success rate has not been
replicated with adult immunizations. Despite an aggressive campaign by the CDC to increase
adult immunization rates, they still remain very poor for all vaccinations (CDC/NCHS, 2014,
Table 75).
Background and Significance
Incidence of Pneumococcal Disease
Streptococcus Pneumoniae (Pneumococcus) was first isolated by Dr. Louis Pasteur in
1881. In the 1940’s, penicillin was discovered and the medical community thought they had a
tool to eradicate Streptococcus Pneumoniae. However, it was discovered that many patients with
invasive Pneumococcal disease (IPD) still died despite antibiotic treatment, especially the elderly
≥65 years old (Plouffe et al., 1996), the young (<2 years old) and those with
immunocompromised states (Hamborsky & Kroger, 2015).
IPD (pneumonia, bacteremia and meningitis) results in significant morbidity and
mortality. Pneumococcal pneumonia makes up >400,000 hospitalizations a year with a case
fatality rate 5% to 7% which may be much higher among elderly persons. There are
also >12,000 cases of Pneumococcal bacteremia without pneumonia a year with a case fatality
rate of 20% but may be as high as 60% for the elderly. The most severe IPD is Pneumococcal
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meningitis. There are 3000 – 6000 cases of Pneumococcal meningitis a year with a case fatality
rate of 8% among children and 22% among adults (Hamborsky & Kroger, 2015).
The first Pneumococcal vaccine was licensed in the United States in 1977 with a 14valent polysaccharide vaccine. In 1983, a 23-valent polysaccharide vaccine was licensed called
PPSV23 (Pneumovax). PPSV23 has been found to be highly effective against IPDs in young
adults. However, its efficacy is markedly decreased in the elderly ≥65 years old (Plouffe et al.,
1996), and the young (<2 years old) (Hamborsky & Kroger, 2015). The first conjugate
Pneumococcal vaccine was not licensed until 2000 with a 7-valent polysaccharide conjugate
vaccine (PCV7) which was then replaced with a 13-valent Pneumococcal conjugate vaccine
licensed in 2010 (Tomczyk, et al., 2014).
While data on immunocompromised patients are lacking, PCV13 has been shown to be
75% effective in preventing IPDs, and 45% effective at preventing non-invasive pneumonia
caused by the 13 strains it covers. PPSV23 has been shown to be 60 to 70% effective in
preventing invasive disease caused by the 23 strains it covers (Bonten et al., 2015). Furthermore,
it has been shown that an initial PCV13 vaccination enhances the protective effects of PPSV23
for most of the serotypes that are found in both vaccines whereas a dose of PPSV23 prior to
PCV13 vaccination did not (Greenberg et al., 2014).
The current standard of care is to vaccinate with PCV13 and PPSV23 all adults ≥ 65 and
all adults aged 19-64 years old with certain immunocompromised states (Appendix B). A
second dose of PPSV23 is also recommended five years after the first PPSV23 dose for these
patients. Those who do not have these conditions but have certain other chronic conditions
(Appendix B) may not be recommended to get PCV13 but are recommended to get a single dose
of PPSV23. Finally, any adult who received their PPSV23 vaccine prior to 65 years of age for
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any reason should have a second dose of PPSV23 after they turn 65 years old (Hamborsky &
Kroger, 2015).
Since the PCV13 recommendations have only been present since 2012 for those with
immunocompromised states and 2014 for those ≥65years old, data is lacking on the PCV13
vaccination rates. Despite the CDC recommendations, nationally, only 21% of adults 19-64
years old at high risk and only 59.7% of adults ≥ 65 receive the Pneumococcal (PPSV23)
vaccination. (CDC/NCHS, 2014, Table 75). This is well below the Healthy People 2020 goal of
90% coverage with the Pneumococcal vaccines for patients ≥65 years old (Hamborsky &
Kroger, 2015).
There are many barriers to adult vaccinations. Only approximately 30% of general
internists or family physicians report that they assess their patients’ vaccination status at every
visit (Hurley et al., 2014). Information systems can be helpful to track vaccinations but only 8%
of general internists and 36% of family physicians use those (Hurley et al., 2014). Another
barrier is the lack of vaccines themselves at the clinics. Due to financial constraints (lack of
insurance coverage, inadequate reimbursements and lack of a VFC type program for adults),
most primary care providers do not stock all the recommended vaccines and instead refer
patients to get those vaccinations at a local pharmacy or at the public health department (Hurley
et al., 2014). Finally, 50% of general internists and family physicians report management of
acute problems taking precedence over vaccinations (Hurley et al., 2014).
Pneumococcus is one of the four major vaccine preventable diseases in the United States
for those ≥65 years of age along with influenza, herpes zoster and pertussis. While
Pneumococcal diseases only contribute to 8% of the incidence of disease ranking it third highest
incidence compared to the other three, it contributes to 25% of the total healthcare utilization of
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these four diseases which sets it second in healthcare utilization behind only influenza (Figure 1)
(McLaughlin, McGinnis, Tan, Mercatante, & Fortuna, 2015).

Figure 1 - Percentage of estimated incidence and direct cost of 4 major Vaccine
preventable diseases in the United States, 2013 for those ≥65 (McLaughlin et al., 2015)

Retail Healthcare Clinics
Retail healthcare clinics started in 2000. These clinics are general staffed by NPs or PAs
and focus on convenient care for minor illnesses as well as vaccinations. The advantages of
retail health clinics are price and convenience. A comparison between the average costs of
common illnesses treated at a retail healthcare clinic vs. physicians’ offices vs. urgent care
centers vs. emergency departments were $110 vs. $166 vs. $156 vs. $570 respectively (Mehrotra,
2009). Furthermore, an estimated 10.6% of the total U.S. and 13.4% of the urban U.S.
population lives within a five minute driving distance of a retail healthcare clinic (Rudavsky,
2009).
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The three largest retail healthcare clinics make up 81% of all retail healthcare clinics in
the United States (Mehrotra, 2009). In 2009, 40% of these retail healthcare clinic visits provided
immunizations for 1.95 million visits resulting in 1.8 million influenza (including H1N1)
vaccinations and almost 60,000 Pneumococcal vaccinations (Uscher-Pines, 2012). This same
study reviewed data from the two largest healthcare clinic chains (accounting for 76% of all
retail health clinic visits) and discovered that Pneumococcal vaccinations for those ≥65 and those
19-64 with high risk for Pneumococcal infections accounted for only 0.6% each of these total
visits or 1.2% of the total clinic visits for these two retail healthcare chains (Uscher-Pines, 2012).
Purpose of Project
The purpose of this evidence-based practice project was to implement a PCV13
vaccination protocol in the Palomar retail healthcare clinic system. Prior to this project, there
was no PCV13 vaccination program in this retail healthcare system.
Theoretical Model
The Provus Discrepancy Evaluation Model was used as a framework for this project
(Provus, 1969). With the Provus Discrepancy Evaluation Model, problem areas are identified by
comparing program performance with an established program design standard. The steps are: 1.
Specify program objectives, 2. Plan evaluation based on the objectives, 3. Collect information on
program accomplishments, 4. Identify difference between program objectives and program
accomplishments and 5. Modify programs (Appendix G).
Practice Change Process
The target population for this project included two populations who receive at least some
of their health care in three locations that are part of the Palomar Expresscare clinics system. The
proposed three sites are located in Albertson’s supermarkets in North inland San Diego region
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and Temecula, staffed by NPs. All of the sites takes most insurance coverage, except traditional
Medicaid and Medicare. The majority of their patients are walk-in customers. While this retail
health clinic system does offer some vaccinations such as influenza and PPSV23 vaccinations,
they currently do not have a PCV13 vaccination protocol despite the recent CDC
recommendations.
Prior to the initiation of the project, a stakeholder’s presentation was made to the Palomar
Expresscare provider staff at their monthly staff meeting where the proposal for the project was
presented. The provider staff (ten NPs and one physician) voted and agreed to implement the
project at their facilities. Next, IRC approval was obtained from both Palomar Health as well as
from the University of San Diego. The Palomar Expresscare provider staff members were then
emailed written PCV13 educational materials and the vaccinations were stocked in the clinics.
An implementation team member went to each clinic to deliver the forms and educational
materials as well as to answer questions. This project duration was four months with the data
collected and evaluated weekly. Project status updates were provided weekly via email as well
as at their monthly staff meetings.
The NPs administered the questionnaires (Appendix C) at the time of evaluation of the
patient in clinic to check for eligibility and contraindications for PCV13 vaccination as well as
whether the patient accepted the vaccination, declined the vaccination, made a follow-up
appointment to receive the vaccination at a later date or was referred elsewhere for the
vaccination. If the patient qualified for and agreed to receive the vaccination, they received the
patient information sheet (Appendix A) as well as the PCV13 VIS sheet (Appendix H). The
PCV13 VIS is developed by the CDC. The vaccination was then administered according to the
clinic’s PCV13 vaccination protocol developed for the clinic (Appendix B). The documentation
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of administering the vaccination was completed on the questionnaire as well as the patient’s
EMR and vaccination card. The healthcare provider finalized the visit and discharged the patient
home.
Those who declined the vaccinations on that date or chose not to receive the vaccinations
at the clinics were either given another appointment to receive the vaccinations or referred to
their PCP or a local pharmacy for the vaccinations. The most common reason for referral to a
local pharmacy was with Medicare patients as the clinic did not accept Medicare insurance
whereas the vast majority of the local pharmacies did.
Advertisement flyers for PCV13 were made available in the clinics for all patients to
view and copies were given to them on request (Appendix D). Name badges with the logo “ask
me about the new pneumonia vaccine” which also had an insert with the prices for the
vaccinations for all the insurances the clinic accepted as well as the self-pay price were given to
the NPs to wear. Completed patient questionnaires were stored in a clipboard in the clinic and
picked up weekly by the project director for data analysis. The data were then entered into a data
collection sheet (Appendix E) for analysis.
Evaluation of Benchmarks
The objective of this program was to implement a protocol for identification and
administration of the PCV13 immunization to all adults ≥65 years old as well as adults 19-64
years of age with certain immunocompromised states that make them high risk for IPDs. The
goal was to demonstrate that it is feasible for retail healthcare clinics to provide this service for
older adult patients. The benchmarks were (1) to offer the PCV13 vaccination to a minimum of
20% of those eligible, and (2) to administer PCV13 vaccinations, or refer elsewhere for
vaccination, to a minimum of 10% of those eligible based on CDC guidelines.
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Cost/Benefit Analysis
The cost of the PCV13 vaccination to our clinic system was $128.40 (the purchase
occurred in ten vial packs costing $1284). The reimbursement for the vaccine ranged from $145
to $180 depending on insurance. For those without insurance, a charge of $160/vaccination was
incurred which is less expensive than the local pharmacies which averaged approximately
$200/vaccination. For those with insurance that was not accepted at the retail healthcare site, a
referral was made to their PCP or a local pharmacy for the vaccination depending on their
insurance and preference. On average, the clinic made a profit of $30/vaccination.
The benefits of PCV13 vaccination are in decreased healthcare costs and a healthier
population. The Quality adjusted life years (QALY) for PCV13 is estimated at $28,900 QALY
compared to $34,600 QALY for PPSV23 (Smith et al., 2012). These calculations do not take
into account herd immunity. It is still not known at this time whether PCV13 will have a similar
herd immunity effect that was seen with PCV7. If so, the benefits of PCV13 may be even
higher.
It is also estimated that giving the PCV13 vaccination based on current recommendations
to those ≥65 and high risk patients 19-64 will decrease the incidence of IPDs from 858 to
833/100,000, decrease the deaths from pneumonia from 1775 to 1749/100,000 and decrease
hospitalizations for Non-Pneumococcal pneumonia from 9292 to 9122/100,000 (Smith et al.,
2012). This would result in 25 less incidence of IPDs, 26 fewer deaths and 170 fever
hospitalizations for non-Pneumococcal pneumonia/100,000 patients vaccinated.
Results
Data analysis extending over the four-month period including November and December
2015 extending through January and February 2016 revealed that 4.3%, 3.8%, 5.9% and 5.3% of
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the total patients seen in the clinic system qualified for the PCV13 vaccination with an average
of 4.8% (Figure 4). During these 4 months a total of 936, 610, 732 and 924 patients were seen in
the Palomar Expresscare system for a total of 3202 patient encounters (Table 1).

Table 1
Total
seen

Number
Eligible

# ≥65
Eligible

# 1964
Eligible

% ≥65
Eligible

% 1964
Eligible

#
Vaccinated
or referred

# ≥65
Vaccinated

# 19-64
Vaccinated

%vaccinated
≥65

%vaccinated
19-64

November

936

40

28

12

70.0

30.0

1

0

1.0

0.0

100.0

December

610

23

10

13

43.5

56.5

0

0

0.0

0.0

0.0

January

732

43

32

11

74.4

25.6

9

8

1.0

88.9

11.1

February

924

49

31

18

63.3

36.7

7

5

2.0

71.4

28.6

3202

155

101

54

65.2

34.8

17

13

4.0

76.5

23.5

Month

Totals

In November, there were 40 patients eligible for the vaccination, 9 of those were offered
the vaccination, 8 of which declined and 1 person was vaccinated. In December, there were 23
eligible patients, 5 were offered vaccination all of whom declined. In January, 43 patients were
eligible, 17were offered the vaccine, 8 declined, 8 were referred elsewhere for vaccination and
one patient made a follow-up appointment for vaccination. In February, there were 49 eligible
patients, 12 were offered the vaccine, 5 declined, 2 were vaccinated and 5 were referred
elsewhere for vaccination (Figure 2). For the 4 months of the study, 31, 18, 26 and 37 eligible
patients were not identified and offered PCV13 vaccination (Figure 2).

17
INCORPORATING AN ADULT PCV13 VACCINATION PROTOCOL

Figure 2 - Prevnar 13 screening and
immunization rates at retail-health
care clinic by month

60

50

Vaccinated
Declined

40

30

20

18
1
9
0

$68,450 $ Clinic profits
$1080

$48,100
$780

$57,350
$930

10

37

26

31

8

8

$33,300

5

Missed
opportunies
$ Society savings

0
5

Nov Eligible Nov Offered Dec Eligible Dec Offered
PCV 13
PCV 13
PCV 13
PCV 13

5

17

9
Jan Eligible
PCV 13

Jan Offered
PCV 13

12

7

Feb Eligible Feb Offered
PCV 13
PCV13

Of those eligible patients, there were 101 patients ≥65 years old compared to 54 patients
who were 19-64 years old with high risk for Pneumococcal infections. This resulted in 65.2% of
those eligible for PCV13 being ≥65 compared to 34.8% for those 19-64 years old. Furthermore,
those ≥65 were more willing to get the PCV13 vaccination with 76.5% of those who were
vaccinated or referred elsewhere for vaccination being ≥65 and only 23.5% being 19-64 years
old (Table 1). This can also be seen based on the percentages of eligible patients vaccinated by
age group and month (Figure 3).
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Figure 3 - Number of Patients
Eligible and Vaccinated by age group
60

50

40

18

11
12

30

20

13

28

32

10

1
8

10
1
0

0
November

31
2
5

0

November
# ≥65 Eligible

December

December

# ≥65 Vaccinated

January
# 19-64 Eligible

January

Feburary

Feburary

# 19-64 Vaccinated

# ≥65 # ≥65
# 19-64 # 19-64
Eligible Vaccinated Eligible Vaccinated
Totals 101
13
54
4

Thus, both benchmarks were achieved since 11% received the PCV13 vaccination while
27.7% were offered the PCV13 vaccination (Figure 4).
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Figure 4 - % of patients eligible and
ultimate vaccination results
100.0
88.9

60.5
47.1
39.5
22.5

21.7

20.9

41.7
24.5
14.3

27.7

3.8
0.0
December

5.9

5.3

11.0
4.8

January

Feburary

Total

22.5

21.7

39.5

24.5

27.7

2.5

0.0

20.9

14.3

11.0

4.3
2.5
November
% eligible offered
% eligible vaccinated
% eligible

4.3

3.8

5.9

5.3

4.8

% declined

88.9

100.0

47.1

41.7

60.5

Discussion
Evidence-based healthcare must be accessible and available to all patients for health
promotion and disease prevention. Pneumococcal vaccinations have been shown to be a costeffective strategy for decreasing the high burden of Pneumococcal disease to our healthcare
system (McLaughlin et al., 2015). Unfortunately, Pneumococcal vaccination rates are poor with
the PPSV23 vaccination rates of 59.7% for those ≥65 and 20% of high risk patients 19-64
vaccinated (CDC/NCHS, 2014, Table 75). As adult PCV13 vaccination recommendations are
new, there is not sufficient data to establish a current benchmark vaccination rate however it is
generally accepted that it is lower than even the abysmal vaccination rates for PPSV23.
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Retail healthcare clinics are becoming increasingly common affording adult community
residents easy access to primary care including vaccinations (Rudavsky, 2009). Since NPs make
up a majority of the staff for these retail healthcare clinics (Mehrotra, 2009), we have an
opportunity to improve the health of not only our patients but to the US healthcare system. As
such, NPs should assume leadership roles in developing vaccination protocols. Vaccination
protocols can also provide good financial revenue for these retail healthcare clinics (UscherPines, 2012) along with providing a service that the current primary care system has clearly
shown itself incapable of effectively providing (Hurley et al., 2014). With our retail healthcare
system vaccination project, approximately 4% to 6% of the patients seen qualify for PCV13
vaccination. This represents a significant vaccination opportunity for providers to give their
patients an important vaccination.
As expected, there was a learning curve with patient screening. The NPs in the project
offered only 22.5% and 21.7% of those eligible in the first 2 months of the project respectively
which increased to 39.5% and 24.5% for the last 2 months of the project. The same trend was
seen with the percent eligible vaccinated being 2.5%, 0%, 20.9% and 14.3% respectively
showing a significant increase in January and February 2016 compared to November and
December 2015. One outcome that was not anticipated included the decrease in the percent of
those who declined the vaccinations in the second half of the project. For November and
December of 2015, 88.9% and 100% of the patients offered PCV13 declined versus only 47.1%
and 41.7% of those offered the vaccine in January and February of 2016. This likely reflected the
NPs being more confident with recommending the vaccination and the patients responding to
that confidence. The percentage of the patients who qualified for PCV13 vaccination was stable
at 3.8% to 5.9% of total patients qualifying for the vaccination (Figure 4).
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There were still many patients who were not properly identified for PCV13 vaccinations.
This was estimated to have cost society a total of $207,200 in estimated healthcare expenditures
from Pneumococcal disease and cost the clinics an estimated $3,330 in revenue for the 4 months
of the project (Figure 2). While this project was a short project with few patients vaccinated it
does show that the retail healthcare clinic system can be an effective venue for improving the
PCV13 vaccination rate.
Insurance funding was a significant barrier for our clinics. The clinics in this project did
not accept Medicare which limited the number of eligible participants to receive vaccinations.
These patients were referred to their PCP or to a pharmacy for vaccination. Due to this
challenge, Expresscare is currently considering adding Medicare coverage for our clinics.
Another barrier in this project was the continued emphasis on acute illnesses and failure
to incorporate more preventative care. As the healthcare system increasingly moves toward
increasing use of electronic medical records (EMR), it can be a valuable resource for enhancing
primary care. One of the initial intentions for this project was to incorporate a vaccination
reminder and the questionnaire into our EMR system which unfortunately did not happen due to
technical problems. This would have improved our project as well as possibly counteracted our
slow start for the project. At this time, the Expresscare clinic system is still looking into
incorporating the changes to our EMR system for long term sustainability beyond the scope of
this project.
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Appendix B: Patient vaccination protocol
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Appendix C: Patient checklist of questions
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Appendix D: Advertisement flyer
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Appendix E: Data collection sheet
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Appendix F: CDC adult immunization schedule 2015
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Appendix G: Provus discrepancy evaluation
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Appendix H: PCV13 Vaccine information statement
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Concluding Essay
Nurses have been integral to the healthcare system for a long time and their roles are
fairly well defined and understood by consumers of healthcare. However, as nurses continue to
expand their roles, there are increasing uncertainties as to the multiple and varied roles of nurses.
The roles and responsibilities of APRN’s (Advanced Practice Registered Nurses) are to
improve the health of their patients and to promote healthcare as a whole. An APRN improves
the health of their patients by providing excellent clinical care through critical appraisal of new
data to incorporate into patient care while navigating the complex healthcare system. An APRN,
specifically a nurse practitioner, must be more than just a great clinician. In order to promote
overall improvements in healthcare, APRNs must care for their patients as well as the
“dynamics” of healthcare. This requires skills in organizational and systems leadership,
healthcare policy and advocacy, and improving inter-professional collaboration with other
members of the healthcare field not just for themselves but for APRNs in general.
The roles of doctoral prepared APRNs are not well understood, mostly due to a lack of
understanding and experience of working with APRNs who hold a doctorate. Most people both
inside and outside of the healthcare field do not know our roles well because they have not had
sufficient exposure to us and our skill sets to really understand what we bring to the table. As
our numbers grow and we become more involved in healthcare this lack of understanding should
lessen. As APRNs get more involved in providing healthcare and patient advocacy, we will be
better understood as a profession. Doctoral APRNs are on the forefront of expanding traditional
roles of nursing and assuming leadership roles in clinical decision making that is integral to
patient care delivery.
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My plans for obtaining my DNP degree has been first and foremost to be a great
practitioner. I highly value the training that I received on critical appraisal of the evidence and I
plan to use it directly on patient management decisions. While there is also a great need out
there for nurse practitioners to take leadership roles in forming policy; that need will have to be
filled by my colleagues. I do not know exactly what setting it will be yet but my future is going
to involve direct patient care. I value the time that I spend with my patients face to face and plan
to care for those who need me as long as I possibly can.

